Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

A group of scientists from the Angiogenesis Unit of the Biomedical Research Centre of La Rioja (CIBIR) has succeeded in creating a vaccine, based on messenger RNA technology, that ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

How does a cell know when it’s been damaged? A molecular alarm, set off by mutated RNA and colliding ribosomes, signals ...

Moderna Japan had planned to build an mRNA drug plant at Shonan Health Innovation Park in Kanagawa prefecture. The company shelved the plan, citing weak demand for vaccines and a poor business ...

Scientists may be on the brink of a groundbreaking medical breakthrough that could transform the way cancer is treated around ...

An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to “wake ...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside ...

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in ...

A new large study from Denmark finds no evidence that aluminum salts used in vaccines are tied to a higher risk of childhood ...